ArticleBritish journal of clinical pharmacology2026
Population pharmacokinetics of TBAJ-587 and its main metabolites-Evaluation of different loading dose strategies and early dose selection.
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04890535 (Phase 1, Partially Blinded, Placebo-Controlled, Randomized, Combined Single Ascending Dose With Food Effect Cohort Trial and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, and PK of TBAJ-587 in Healthy Adults), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 1, Partially Blinded, Placebo-Controlled, Randomized, Combined Single Ascending Dose With Food Effect Cohort Trial and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, and PK of TBAJ-587 in Healthy Adults
Who cites it
2 citing papers in PubMed.
- Article
- Research overview-2025: integrating scientific progress to accelerate global tuberculosis elimination.Frontiers in tuberculosis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
aimThe rise of drug-resistant tuberculosis (TB) poses a need for new drugs and combinations. TBAJ-587, a new diarylquinoline (DARQ), has shown promising efficacy in preclinical studies. This work aimed to describe the pharmacokinetics (PK) of TBAJ-587 and its metabolites M2 and M3 after single ascending dosing in healthy volunteers and to develop a simultaneous population PK model. In addition, to explore different doses in relation to efficacy and safety and to assess the impact of loading doses on exposure levels of TBAJ-587 and its metabolites.
methodsPharmacokinetic samples from 42 healthy volunteers following a single dose (25, 50, 100, 200, 400 or 800 mg) were collected for up to Day 126. Population pharmacokinetic modelling was conducted using nonlinear mixed-effects modelling in NONMEM. Simulations from final model were performed to compare against efficacy targets derived from the first-in-class DARQ bedaquiline and safety references based on preclinical studies. RESULTS AND
conclusionsThe final model simultaneously described the PK of TBAJ-587, M2 and M3 well. Simulations of final model identified that all simulated doses and regimens resulted in exposures that were below the safety references. A loading dose for 2 weeks resulted in initially higher concentrations, but a limited difference in exposure at 4 weeks and onwards, compared with no loading dose. A 100 mg once daily dose and higher reached the efficacy targets and can be studied further in combinations in phase 2a studies. Name of trial: Evaluation of the Safety, Tolerability, PK of TBAJ-587 in Healthy Adults. REGISTRATION NUMBER: NCT04890535.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.